PROCEPT BioRobotics Corporation Securities Class Action

Class Period

February 28, 2024 - February 25, 2026

Motion Deadline

September 22, 2026|53 days left

Please submit the form below if you believe you have incurred losses.

First Name *

Last Name *

Email Address *

Phone Number*

Address Line 1

City

State / Province / Region

Postal Code

Country

Investment Details

Estimated Losses *

Do you still retain shares?

Transactions Information

Select a file or drag and drop here

PDF, XLS, or CSV, file size no more than 25MB

Additional information

By clicking the submit button above, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Pomerantz LLP ("Pomerantz" or "The Firm"), and that the submission or receipt of information to the Firm or one of its attorneys via this form, website, e-mail or telephone does not create an attorney-client relationship. Prior results do not guarantee a similar outcome in future cases.

Pomerantz LLP does not share your information with others. There is no cost or obligation for you to submit. By submitting this form, you are authorizing us to contact you regarding this case and/or future cases.

Allegations

On August 6, 2025, Procept announced earnings for its second fiscal quarter of 2025, revealing that Procept had only sold approximately 12,750 handpieces in the United States during the quarter. During Procept’s earnings call, Chief Financial Officer Kevin Waters reported that Procept expected to ship approximately 13,350 units in the following quarter, significantly below consensus estimates of more than 13,840 units. Procept’s quarterly handpiece sales guidance also implied that Procept would need to grow handpiece sales by approximately 25% year-over-year in the fourth quarter in order to meet Procept’s annual unit sales guidance. In addition, then-Chief Executive Officer Reza Zadno revealed that Procept was eliminating the role of Chief Commercial Officer in order to “strengthen” Procept’s “commercial execution.” On this news, Procept’s stock price fell approximately 16% over a two-day trading period. Then, on November 4, 2025, Procept announced earnings results for its third fiscal quarter of 2025, revealing that Procept had only sold 13,225 handpieces during the quarter, which missed Procept’s sales guidance issued during the prior quarter. During the corresponding conference call, CFO Waters further revealed that Procept was reducing its annual handpiece sales guidance by 1,000 units, down from 53,000 units to 52,000 units to allow for the “optimization of field inventory.” CEO Larry L. Wood further admitted that Procept had not “been managing customer inventory by establishing par levels” and that some customers were “probably carrying too much inventory.” On this news, Procept’s stock price fell more than 10% over a two-day trading period. Finally, on February 25, 2026, Procept announced earnings results for its fourth fiscal quarter and year ending December 31, 2025. Procept revealed that handpiece sales had materially exceeded procedures in every quarter since the first fiscal quarter of 2023, a differential which had consistently grown over time, ultimately resulting in cumulative excess field inventory of more than 10,000 units. Procept further revealed that quarterly handpiece unit sales in the United States had declined significantly from 13,225 units in the third quarter to 9,400 units, representing a sequential decline of nearly 30%. On this news, Procept’s stock price fell more than 18% over a two-day trading period.

Lead Plaintiff

If you have qualifying losses, you may be eligible to serve as Lead Plaintiff. Acting as a representative for all class members seeking recovery in the lawsuit, the Lead Plaintiff plays an important role in the litigation, including selecting a law firm to serve as Lead Counsel and approving the final settlement. There is no cost whatsoever to seek or participate as a Lead Plaintiff. The Lead Plaintiff may also receive a monetary award for their participation in the suit.

About the Firm

Founded in 1936, Pomerantz LLP is the oldest law firm in the world dedicated to championing investor rights. Throughout its history, the Firm has won landmark decisions that have initiated historic corporate governance reforms and shaped the law to better protect shareholders. Pomerantz has successfully resolved hundreds of securities class actions as Lead Counsel, recovering billions of dollars on behalf of defrauded investors with many settlements breaking previously held records. Pomerantz is headquartered in New York City, with offices in Los Angeles, Chicago, Paris, London, and Tel Aviv.